Psychopharmacology Unit (PPU) |
Instruments |
|
| AES | Antipsychotic Experience Scale |
| AIMS | Abnormal Involuntary Movement Scale for tardive dyskinesia |
| Barnes Akathisia | Scale for drug-induced restlessness |
| BDI | Beck Depression Inventory |
| BPRS | Brief Psychiatric Rating Scale |
| Calgary Scale | Scale for depression |
| CGI | Clinical Global Impressions Scale |
| DAI | Drug Attitude Inventory |
| ECG | Electrocardiogram |
| HAM-D | Hamilton Depression Scale |
| Laboratory tests | Levels of whole blood and plasma 5HT (serotonin), HVA (homovanillic acid), plasma levels of antipsychotic, prolactin, caffeine, cotinine, and nicotine |
| Movement tests | Electromechanical tests of movement disorders |
| Neuropsychologic | Battery of assessments measuring neurocognitive function, including Stroop Color-Word naming, Spatial Working Memory Test, Wisconsin Card Sort, and Digit Span |
| Neurosoft Signs | Battery to measure neurologic deficits |
| PANSS | Positive and Negative Symptom Scale |
| Physical exam | Complete review of systems, including weight, temperature, blood pressure |
| QLS | Quality of Life Scale |
| SANS | Scale for the Assessment of Negative Symptoms |
| SCID-P | Diagnostic tool for psychiatric disorders |
| SCL-90 | Subjective Symptom Check-List |
| SERS | Subjective Extrapyramidal Rating Scale |
| Sexual Functioning | Questionairre measuring changes in sexual function |
| Simpson-Angus | Scale for parkinsonian movement disorders |
| Smoker's Profile | Questionairre capturing and quantifying smoking behavior |
| SRS | Subjective Response Scale |
| WAIS-R | Cognitive test of intelligence |
| WRAT-3 | Reading |
| Y-BOCS | Yale-Brown Obsessive Compulsive Scale |
Intervention Techniques |
|
| Community Re-Entry Program | A pilot study of the outcome of an 8-hour rehabilitation training curriculum with Trainer's Manual, Participant's Workbook, and Demonstration Video for use in assisting individuals with schizophrenia or schizoaffective disorder to successfully transition from an inpatient hospitalization setting to community living and utilizing aftercare services. This module has been empirically validated in two studies, and publications are available reporting its efficacy |
| Management of Risk for Relapse in Schizophrenia Program | A study of the outcome of antipsychotic treatment combined with 2-6 hours per week of a training curriculum including Medication Management, Symptom Management, Social Problem Solving, and Successful Living for individuals with schizophrenia or schizoaffective disorder. Half of the participants also receive In-Vivo Assisted Skills Training, which entails intensive personalized case management and training in the home and community settings. Publicatons are available showing the effectiveness of previous work with this program |